Mhairi Maskew1, A Patrick MacPhail, Denise Whitby, Matthias Egger, Matthew P Fox. 1. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.mmaskew@heroza.org
Abstract
BACKGROUND: The possible impact of coinfection with the Kaposi sarcoma-associated herpes virus (KSHV) on the response to antiretroviral therapy (ART) is unknown. Prospective studies are rare, particularly in Africa. METHODS: We enrolled a prospective cohort of HIV-infected adults initiating ART in Johannesburg, South Africa. The subjects were defined as seropositive to KSHV if they were reactive to either KSHV lytic K8.1 or latent Orf73 antigen or to both. The subjects were followed from ART initiation until 18 months of treatment. HIV viral load and CD4 counts were tested 6 monthly. Linear generalized estimating and log-binomial regression models were used to estimate the effect of KSHV infection on immunologic recovery and response and HIV viral load suppression within 18 months after ART initiation. RESULTS: Three hundred eighty-five subjects initiating ART from November 2008 to March 2009 were considered to be eligible including 184 (48%) KSHV+. The KSHV+ group was similar to the KSHV- in terms of age, gender, initiating CD4 count, body mass index, tuberculosis, and hemoglobin levels. The KSHV+ group gained a similar number of cells at 6 [difference of 10 cells per cubic millimeter, 95% confidence interval (CI): -11 to 31], 12 (3 cells per cubic millimeter, 95% CI: -19 to 25), and 18 months (24 cells per cubic millimeter, 95% CI: -13 to 61) compared with that gained by the KSHV- group. Adjusted relative risk of failure to suppress viral load to <400 copies per milliliter (1.03; 95% CI: 0.90 to 1.17) were similar for KSHV+ and KSHV- by 6 months on treatment. CONCLUSIONS: In a population with a high KSHV prevalence, HIV-positive adults coinfected with KSHV achieved similar immunologic and virologic responses to ART early after treatment initiation compared with those with KSHV-.
BACKGROUND: The possible impact of coinfection with the Kaposi sarcoma-associated herpes virus (KSHV) on the response to antiretroviral therapy (ART) is unknown. Prospective studies are rare, particularly in Africa. METHODS: We enrolled a prospective cohort of HIV-infected adults initiating ART in Johannesburg, South Africa. The subjects were defined as seropositive to KSHV if they were reactive to either KSHV lytic K8.1 or latent Orf73 antigen or to both. The subjects were followed from ART initiation until 18 months of treatment. HIV viral load and CD4 counts were tested 6 monthly. Linear generalized estimating and log-binomial regression models were used to estimate the effect of KSHV infection on immunologic recovery and response and HIV viral load suppression within 18 months after ART initiation. RESULTS: Three hundred eighty-five subjects initiating ART from November 2008 to March 2009 were considered to be eligible including 184 (48%) KSHV+. The KSHV+ group was similar to the KSHV- in terms of age, gender, initiating CD4 count, body mass index, tuberculosis, and hemoglobin levels. The KSHV+ group gained a similar number of cells at 6 [difference of 10 cells per cubic millimeter, 95% confidence interval (CI): -11 to 31], 12 (3 cells per cubic millimeter, 95% CI: -19 to 25), and 18 months (24 cells per cubic millimeter, 95% CI: -13 to 61) compared with that gained by the KSHV- group. Adjusted relative risk of failure to suppress viral load to <400 copies per milliliter (1.03; 95% CI: 0.90 to 1.17) were similar for KSHV+ and KSHV- by 6 months on treatment. CONCLUSIONS: In a population with a high KSHV prevalence, HIV-positive adults coinfected with KSHV achieved similar immunologic and virologic responses to ART early after treatment initiation compared with those with KSHV-.
Authors: Dimitra Bourboulia; Diana Aldam; Dimitrios Lagos; Elizabeth Allen; Ian Williams; David Cornforth; Andrew Copas; Chris Boshoff Journal: AIDS Date: 2004-02-20 Impact factor: 4.177
Authors: A Kovacs; M Schluchter; K Easley; G Demmler; W Shearer; P La Russa; J Pitt; E Cooper; J Goldfarb; D Hodes; M Kattan; K McIntosh Journal: N Engl J Med Date: 1999-07-08 Impact factor: 91.245
Authors: N A Smith; C A Sabin; R Gopal; D Bourboulia; W Labbet; C Boshoff; D Barlow; B Band; B S Peters; A de Ruiter; D W Brown; R A Weiss; J M Best; D Whitby Journal: J Infect Dis Date: 1999-09 Impact factor: 5.226
Authors: John Wilkinson; Alethea Cope; Jas Gill; Dimitra Bourboulia; Peter Hayes; Nesrina Imami; Toru Kubo; Anne Marcelin; Vincent Calvez; Robin Weiss; Brian Gazzard; Chris Boshoff; Frances Gotch Journal: J Virol Date: 2002-03 Impact factor: 5.103
Authors: Mhairi Maskew; A Patrick Macphail; Denise Whitby; Matthias Egger; Carole L Wallis; Matthew P Fox Journal: Infect Agent Cancer Date: 2011-11-17 Impact factor: 2.965
Authors: J P S Servato; A M Loyola; P H R Spini; T H Spini; P R de Faria; Sérgio Vitorino Cardoso Journal: Infection Date: 2013-07-24 Impact factor: 3.553
Authors: Michael E Herce; Noel Kalanga; Emily B Wroe; James W Keck; Felix Chingoli; Listern Tengatenga; Satish Gopal; Atupere Phiri; Bright Mailosi; Junior Bazile; Jason A Beste; Shekinah N Elmore; Jonathan T Crocker; Jonas Rigodon Journal: J Int AIDS Soc Date: 2015-05-29 Impact factor: 5.396
Authors: Matthew P Fox; Mhairi Maskew; Alana T Brennan; Denise Evans; Dorina Onoya; Given Malete; Patrick MacPhail; Jean Bassett; Osman Ebrahim; Dikeledi Mabotja; Sello Mashamaite; Lawrence Long; Ian Sanne Journal: BMJ Open Date: 2017-06-10 Impact factor: 2.692